scholarly journals Penetration, distribution, and elimination of remofuscin/soraprazan in Stargardt mouse eyes following a single intravitreal injection using pharmacokinetics and transmission electron microscopic autoradiography: Implication for the local treatment of Stargardt’s disease and dry age‐related macular degeneration

2020 ◽  
Vol 8 (6) ◽  
Author(s):  
Sylvie Julien‐Schraermeyer ◽  
Barbara Illing ◽  
Alexander Tschulakow ◽  
Tatjana Taubitz ◽  
Jamil Guezguez ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Intravitreal Injection ◽  
Local Treatment ◽  
Age Related Macular Degeneration ◽  
Electron Microscopic ◽  
Electron Microscopic Autoradiography ◽  
Stargardt's Disease ◽  
Age Related ◽  
Transmission Electron ◽  
Transmission Electron Microscopic

scholarly journals Incidence of elevated intraocular pressure after intravitreal injection in Japanese patients with age-related macular degeneration

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Maiko Maruyama-Inoue ◽  
Tatsuya Inoue ◽  
Shaheeda Mohamed ◽  
Yoko Kitajima ◽  
Shoko Ikeda ◽  
...  
Keyword(s):  
Risk Factors ◽  
Intraocular Pressure ◽  
Macular Degeneration ◽  
Intravitreal Injection ◽  
Odds Ratio ◽  
Japanese Patients ◽  
Age Related Macular Degeneration ◽  
Age Related ◽  
Elevated Intraocular Pressure ◽  
History Of

AbstractThe purpose of this study was to report the incidence of elevated intraocular pressure (IOP) after intravitreal injection (IVI) of anti-vascular endothelial growth factor (VEGF) in Japanese patients with age-related macular degeneration (AMD). A retrospective study of chart review of patients who underwent ≥ 10 intravitreal anti-VEGF injections between April 2009 and December 2019 was conducted. Elevated IOP was defined as IOP ≥ 25 mmHg at one visit. Cases with elevated IOP resulting from IVI were identified. Furthermore, the association between elevated IOP and some parameters, as the risk factors that influence elevated IOP, was investigated. A total of 402 eyes of 370 patients were included in this study. Twenty-eight eyes of 26 patients (7.0%) were identified as cases with elevated IOP after IVI. The mean time of elevation after baseline was 50.6 ± 26.5 months. History of glaucoma (p = 0.021; odds ratio, 5.85), treatment modality (p = 0.019; odds ratio, 6.32), and total number of injections (p = 0.003; odds ratio, 1.03) were significantly associated with elevated IOP. A late complication of elevated IOP is associated with IVI in patients with AMD. Particularly, history of glaucoma and treat and extend regimen with frequent injections were found to be risk factors of elevated IOP.

Intravitreal Injection of Ziv-Aflibercept in Patient With Refractory Age-Related Macular Degeneration

2015 ◽  
Vol 46 (1) ◽  
pp. 91-94 ◽  
Author(s):  
João Rafael de Oliveira Dias ◽  
Camilla Oliveira Xavier ◽  
André Maia ◽  
Nilva Simeren Bueno de Moraes ◽  
Carsten Meyer ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Intravitreal Injection ◽  
Age Related Macular Degeneration ◽  
Age Related

scholarly journals Effect of intravitreal injection of aflibercept on blood coagulation parameters in patients with age-related macular degeneration

2020 ◽  
Vol 12 ◽  
pp. 251584142090392
Author(s):  
Constantinos D. Georgakopoulos ◽  
Olga E. Makri ◽  
Athina Pallikari ◽  
Konstantinos Kagkelaris ◽  
Panagiotis Plotas ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Blood Coagulation ◽  
Intravitreal Injection ◽  
Age Related Macular Degeneration ◽  
Intravitreal Injections ◽  
Clinical Effects ◽  
Coagulation Parameters ◽  
Age Related ◽  
Increased Risk ◽  
Treatment Naïve

Purpose: Treatment with intravitreal injections of anti-vascular endothelial growth factor agents has been associated with an increased risk of arterial thromboembolic events. The aim of the present pilot study was to assess the effect of a single intravitreal injection of aflibercept on coagulation. Methods: Treatment-naïve patients with age-related macular degeneration ( n = 47), who were scheduled to undergo treatment with intravitreal injections of aflibercept, were enrolled. None of the included patients received any anticoagulation therapy or had a history of a recent arterial thromboembolic event. Blood samples were collected before the first intravitreal injection, and at 7 and 30 days after aflibercept administration. We evaluated coagulation parameters, such as platelet count and plasma fibrinogen and D-dimer levels; functional clotting parameters, such as prothrombin time, international normalized ratio, and activated partial thromboplastin time; and anticoagulant parameters, such as the levels of Proteins S and C. Results: The levels of all of the evaluated biomarkers were within the normal range at baseline and at both the time points throughout the study. No statistically significant changes were observed in any of the measured parameters at 1 week and 1 month after aflibercept administration. Conclusion: A single intravitreal injection of aflibercept in treatment-naïve patients with exudative age-related macular degeneration has no statistically significant effect on blood coagulation parameters for up to 1 month after aflibercept administration. Our results also provide an explorative statistical data, and further studies are required to evaluate any significant clinical effects of aflibercept on blood coagulation parameters. ClinicalTrials.gov ID: NCT03509623.

Macular Hole after Single Intravitreal Injection of Ranibizumab in a Patient with Age-Related Macular Degeneration

2013 ◽  
Vol 54 (7) ◽  
pp. 1130 ◽  
Author(s):  
Jong Min Kim ◽  
Jun Won Jang ◽  
Sung Eun Kyung ◽  
Moo Hwan Chang
Keyword(s):  
Macular Degeneration ◽  
Intravitreal Injection ◽  
Macular Hole ◽  
Age Related Macular Degeneration ◽  
Age Related

Blood coagulation parameters after intravitreal injection of aflibercept in patients with neovascular age-related macular degeneration

2017 ◽  
Vol 38 (6) ◽  
pp. 2397-2402
Author(s):  
Hasan Altinkaynak ◽  
Meltem Ece Kars ◽  
Piraye Zeynep Kurkcuoglu ◽  
Nagihan Ugurlu
Keyword(s):  
Macular Degeneration ◽  
Blood Coagulation ◽  
Intravitreal Injection ◽  
Age Related Macular Degeneration ◽  
Coagulation Parameters ◽  
Age Related
Sign in / Sign up

Export Citation Format

Share Document